DB
KLRS

Dmitry Balyasny’s Kalaris Therapeutics KLRS Stock Holding History

Dmitry Balyasny’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-693
Closed -$11.5K – 3253
2024
Q2 		$11.5K Buy
+693
New +$12.2K ﹤0.01% 2488
2023
Q1 		– Sell
-1,474
Closed -$174K – 3245
2022
Q4 		$174K Buy
+1,474
New +$250K ﹤0.01% 2160

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Dmitry Balyasny's KLRS Position: Q3 2024 in Review

Dmitry Balyasny sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 693 shares — an estimated $11.5K sold.

Dmitry Balyasny first reported a position in KLRS in Q4 2022 and held it in 2 quarters. The position peaked at $174K in Q4 2022. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Dmitry Balyasny reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 693 Kalaris Therapeutics shares in Q3 2024, an estimated $11.5K.
  • Dmitry Balyasny first reported a position in Kalaris Therapeutics in Q4 2022 and held it in 2 quarters.
  • Dmitry Balyasny's Kalaris Therapeutics position peaked at $174K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.